In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on Biohaven Pharmaceutical Holding Co Ltd (BHVN). The company’s shares opened today at $50.02, close to its 52-week high of $50.65.
According to TipRanks.com, Rajavelu is a 2-star analyst with an average return of 1.2% and a 54.2% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Jazz Pharmaceuticals, and Aerie Pharma.
Biohaven Pharmaceutical Holding Co Ltd has an analyst consensus of Strong Buy, with a price target consensus of $71, which is a 41.9% upside from current levels. In a report issued on March 4, Needham also maintained a Buy rating on the stock with a $56 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $50.65 and a one-year low of $16.50. Currently, Biohaven Pharmaceutical Holding Co Ltd has an average volume of 461.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.
